Denali Therapeutics Inc

DNLI remains in a Stage 2 advancing phase above the rising 50-day SMA, but the recent pullback under down-sloping 9- and 20-period EMAs signals a corrective reset. Medium-term bias stays bullish, yet short-term timing is unfavorable; execution should be deferred into the 50-day SMA support zone or until price reclaims the short EMAs with clear acceptance.

• ↑$195M PRV sale boosts cash runway for Alzheimer programs
• ↑Avlayah FDA approval validates TransportVehicle platform credibility
• ↓Profitability severely negative and earnings yield deeply subpar